Transient antibody production service

We can start from hybridoma cell lines, purified antibody samples, or antibody sequences.
Beyond production, our team can also engineer and optimize your antibody to improve developability and fine-tune reactivity through:

• Affinity maturation
• Humanization
• Bispecific antibody design
• Antibody-drug conjugate (ADC) development
• Reformatting (e.g., isotype switching)

This means you can go from basic production to advanced engineering with a single partner.

It depends on both the format of your antibody (VHH, scFv, Fab, Fc-fusion proteins, IgG, etc.) and its final application.

• For full-length antibodies, mammalian systems (CHO and HEK) are still the gold standard, as they ensure proper folding and human-like glycosylation — two critical features for therapeutic efficacy and safety.
• For fragments (scFv, Fab, VHH), alternative systems such as yeast or bacteria may be preferable to achieve high and cost-effective yields while avoiding the need for stable cell line development.

Our experts will guide you to the best choice depending on your goals.

Thanks to our optimized protocols and extensive expertise, we guarantee:

• At least 1 mg of purified antibody for every project
• Access to multiple expression systems, including our proprietary XtenCHO™ Race system, delivering 2× higher yields on average compared to industry-leading platforms

With ProteoGenix, your project is secured from the start.

Our recombinant antibody service covers a comprehensive range of formats and isotypes, tailored to your research or therapeutic needs:

• Antibody isotypes: IgG, IgM, IgA, IgE, IgD – each with unique functions, from immune defense (IgM, IgA) to cancer therapy (IgG via ADCC/CDC) or allergy studies (IgE).
• Bispecific antibodies: Dual-targeting molecules driving innovation in immunotherapy.
• scFv (Single-chain variable fragment): Compact, engineered fragments retaining specificity, ideal for diagnostics and research.
• Fab (Fragment antigen-binding): Fc-free fragments for applications where effector functions are not required.
• VHH (Nanobodies): Single-domain camelid antibodies — small, stable, and versatile.
• Antibody Fusion Proteins: Combining antibody specificity with the function of another protein for advanced applications (e.g., targeted delivery, purification).

Not sure which format suits your project? Our scientific team is here to help you choose the most effective option.

Recombinant technology is revolutionizing therapeutic and research antibody development. Compared to traditional methods, it offers:

• Ease of engineering & reformatting

Gain precise genetic control over structure and function. Adapt your antibody through:

• • Reformatting (species, isotype, or subtype switching)
  • Humanization and affinity maturation
  • Engineering of bispecifics, ADCs, or fragments (Fab, Fab2, scFv)
• Optimal reproducibility

Eliminate cell line drift or mutations common in hybridomas. Enjoy consistent, standardized production batch after batch.

• High purity

No serum contaminants. High purity ensures optimal performance and reproducible results in all applications.

• Animal-free production

Ethical and efficient — recombinant methods avoid animal use at every stage, aligning with the highest standards of biomedical research.

In short: recombinant production means better control, higher quality, and faster timelines, while future-proofing your antibody development.